Bio Blast Pharma Ltd. Культура компании

Mr. Fredric D. Price, also known as Fred, has been the Chief Executive Officer at Bioblast Pharma Ltd. since July 2016. Mr. Price served as the Chairman, Chief Executive Officer and President of Chiasma Inc. from 2008 to 2013. Mr. Price served as the Chief Executive Officer at Chiasma (Israel) Ltd. and served as its Acting Chief Executive Officer. He served as the Chairman and Chief Executive Officer of BioMarin Pharmaceutical Inc. from October 31, 2000 to August 2004. From September 1994 to September 2000, he served as the President and Chief Executive Officer for Applied Microbiology/AMBI, a biotechnology and nutrition company from 1994 to 2000. He was Founder of RxFDP and served in it from 1986 to 1991. From July 1991 to September 1994, he served as Vice President of Finance & Administration and Chief Financial Officer of Regeneron Pharmaceuticals. From March 1986 to July 1991, Mr. Price served as pharmaceuticals and biotechnology industry strategy consultant. For over 13 years, he was employed by Pfizer Pharmaceuticals, where he served as a Vice President with both staff and line responsibilities. He served at NXXI Inc. He has been the Executive Chairman of BioBlast Pharma Ltd., since April 24, 2012. He served as Executive Chairman of Chiasma (Israel) Ltd., since 2008 and served as its Director. Since August 2004, he has been the Chairman of the Empirical Physician & Patient Information Census, or EPPIC and a member of the general partnership of BioDevelopment Ventures. He served as Executive Chairman of Chiasma Inc. He served as an Executive Chairman of Peptimmune, Inc. from August 2007 to 2011 and served as its Executive Director. Mr. Price served as the Executive Chairman of Omrix Biopharmaceuticals Inc., from January 2005 to May 2008. He served as Non Executive Chairman of Bio Blast Pharma Ltd. from April 2012 to April 2014. He serves as a Director of Bioblast Pharma Ltd. He serves as a Member of the Advisory Board at FDNA Inc. He served as a Director of Alexion Montr???al Corp. (formerly, Enobia Pharma Inc.), from May 2006 to 2012. He served as a Director of Morria Biopharmaceuticals Plc (also known as Celsus Therapeutics Plc) since June 20, 2013. He served as a Director of Gilead Pharmasset LLC (Gilead Pharmasset Inc.) from March 8, 2007 to March 17, 2010. He served as a Director of BioMarin Pharmaceutical Inc., from October 2000 to August 2004 and Omrix Biopharmaceuticals, Inc. since January 2005. He served as a Director of Applied Microbiology at AMBI Inc., from September 1994 to September 2000. He is a co-inventor of 12 issued U.S. patents and one U.S. patent application. Mr. Price received a B.A. from Dartmouth College and an M.B.A. from the Wharton School of the University of Pennsylvania.

Ms. Dana Gelbaum has been the Chief Commercial Officer of Bioblast Pharma Ltd., since November 1, 2016. Ms. Gelbaum served as Vice President of Global Marketing and Corporate Development at Chiasma, Inc. since November 15, 2016. She served as Vice President of Commercial Planning at Chiasma (Israel) Ltd. and served as its Vice President of BD and Supply Chain and Vice President of Pre-Commercial and Supply Chain. Ms. Gelbaum served as Vice President of Commercial Planning at Chiasma, Inc. from December 2011 to January 5, 2016. She served as Director of Business Development at Chiasma, Inc. since joining in 2009. Ms. Gelbaum served as Director of Business Development at Recoly NV. She served as an Associate at Johnson & Johnson Development Corporation (now Johnson & Johnson Innovation - JJDC, Inc.) since December 2003, focussed on investments in biopharma companies in Europe and Medical Device companies in Israel. She was responsible for the deal flow management of the Israeli market. She was also engaged in supporting the investment process in the European market. She started her career as an Analyst at Ernst & Young LLP and then served as a Manager of Young Life Science Corporate Department - Israel. She was engaged in providing business and strategic consulting for Israeli life science start up companies. Following E&Y, she served as the Director of Business Development for RAD BioMed Ltd. (also known as RAD BioMed Accelerator, Rad-BioMed Incubator). Ms. Gelbaum holds an MSc. degree cum laude in Molecular and Cellular Biology and an M.B.A. degree in Finance both from Tel Aviv University.

Dr. Dalia Megiddo, Ph.D., M.D., MBA, is the Managing Partner at InnoMed Medical Device Innovations. Dr. Megiddo focuses on life science investments at Jerusalem Global Ventures, where she is a General Partner. She serves as the President at Academia Medica. She is a Co-Founder of Bio Blast Pharma Ltd. and served as its Advisor since November 16, 2015 until November 21, 2015. She has been involved in the Life Science Venture Capital Industry since 1999 and is well recognized as one of the leaders in the healthcare investment community both in Israel and internationally. Dr. Megiddo served as Chief Development Officer at Bio Blast Pharma Ltd. since February 2, 2015. She served as the President of Bio Blast Pharma Ltd. until February 2, 2015 and its Chief Executive Officer since January 22, 2012 until February 2, 2015. She was the Founder and Managing Partner at 7 Health Ventures Ltd., and 7Health Ventures. She served as Managing Partner of InnoMed Fund and Jerusalem Global Ventures. Since 1994, Dr. Megiddo served as Chief Editor at Academia Medica, she has a rich background in life science entrepreneurship and investing. Prior to Jerusalem Global Ventures, she was a Consultant to numerous venture capital funds. An entrepreneur by nature, in 1987, she founded the Israeli medical audio magazine, The Journal Club; and in 1994, she founded Academia Medica, a multimedia medical teaching program. Prior to founding these businesses, Dr. Megiddo was a member of the faculty of the Department of Family Medicine at the Hebrew University-Hadassah Medical Health Center. She has been Director of Bio Blast Pharma Ltd., since January 22, 2012 and Foamix Pharmaceuticals Ltd., since May 16, 2016. She served as a Director of Tulip Medical Ltd., and Humavox Ltd., until September 28, 2017. She served as a Director of Alcobra Ltd. since February 2008 and Impliant, Inc. She served on the Board of AngioScore Inc. She served as a Director of Chiasma (Israel) Ltd. (Chiasma Inc.) and IntelliDx Inc. (formerly Glucon Medical Ltd.). She served as a Director of Given Imaging Ltd. since October 2001 and Elron Electronic Industries Limited since January 2003. She served as a Director of Barnev Inc. From 1981 to 1986, Dr. Megiddo practiced family medicine at the Hebrew University Hadassah Medical Health Center. She has authored several articles in Israeli and international medical journals. Her work has garnered both national and international recognition, including the Annual Award of the Israel Gerontology Society for her publication of ???Domestic Care Dependency in the Aged??? in 1985; a Merit of Excellence Award in the annual Israel Prime Minister's Software Competition in 1997; and the US Apple Gold Award for Education Media in 1998. She is a frequent speaker at international medical conferences, including the World Conference on Family Medicine, the AAFP 47th Annual Scientific Assembly, the Third European Congress on Family Medicine and the Radiological Society of North America. Dr. Megiddo holds an M.D. in Medicine from Hebrew University, Jerusalem and an M.B.A. from Kellogg Recanati International as well as an Executive M.B.A. program from Tel Aviv University and North Western University.

Mr. Chaime Orlev has been the Chief Financial Officer and Vice President of Finance & Administration of Bioblast Pharma Ltd. since September 2016 and since December 7, 2016 respectively. Mr. Orlev joined Bioblast in September 2016. Prior to Bioblast, from 2011 to 2016, he served as Vice President of Finance and Administration in Chiasma (NASDAQ: CHMA), a biopharma company focused on improving the lives of patients with rare diseases, where he was instrumental in Chiasma's multiple fund raising rounds and in taking it through its successful IPO. Prior to Chiasma, he was a financial consultant to several Israeli biotechnology and medical device companies from 2008 to 2010. From 2008 to 2009, Mr. Orlev served as Chief Financial Officer of Oramed Pharmaceuticals Inc (NASDAQ: ORMP). He received his M.B.A. from the Leon Recanati Graduate School of Business Administration at the Tel Aviv University and a B.A. in Business Administration from the College of Business in Israel. Mr. Orlev is a Certified Public Accountant under the laws of Israel.